牛肺表面活性物质联合经鼻气道正压通气治疗新生儿呼吸窘迫综合征的临床价值

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical value of Bovine Pulmonary Surfactant combined with nasal-continuous positive airway pressure ventilation (NCPAP) in the treatment of neonatal respiratory distress syndrome (NRDS).Methods From March 2018 to October 2019,88 cases of NRDS diagnosed and treated in our department were randomly divided into the observation group and the control group according to the envelope method,44 cases in each group.Both groups were treated with NCPAP,and the observation group was treated with Bovine Pulmonary Surfactant in addition.The clinical symptom improvement,the blood gas analysis index,ventilator ventilation time,oxygen therapy time,hospitalization time and the incidence of complications between the two groups were compared.Results The disappearance time of cyanosis and dyspnea in the observation group was shorter than that in the control group,the difference was statistically significant (P<0.05).The blood gas analysis indexes both improved in the two groups after treatment,and the blood oxygen partial pressure of the observation group was higher than that of the control group,and the partial pressure of carbon dioxide was lower than that of the control group,the differences were statistically significant (P<0.05).The ventilator ventilation time,oxygen therapy time and hospitalization time of the observation group were shorter than those of the control group,the differences were statistically significant (P<0.05).There was no significant difference in the total incidence of complications between the two groups (P>0.05).Conclusion Compared with using NCPAP alone,Bovine Pulmonary Surfactant combined with NCPAP is more effective in the treatment of NRDS,promoting the earlier elimination of clinical symptoms,improving blood gas analysis results,shortening ventilation time,and reducing the risk of complications.So it is worth promoting in clinical application.

Key words： Neonatal respiratory distress syndrome Bovine Pulmonary Surfactant Nasal-continuous positive airway pressure ventilation Clinical value

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LONG Yu-yu

Cite this article:

LONG Yu-yu. Clinical value of Bovine Pulmonary Surfactant combined with nasal-continuous positive airway pressure ventilation in the treatment of neonatal respiratory distress syndrome[J]. 中国当代医药, 2020, 27(30): 4-7.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I30/4

[1]	曾德润.不同胎龄新生儿呼吸窘迫综合征高危因素及临床分析[J].医学综述，2016，22（10）：2024-2027.
[2]	崔爱叶.肺表面活性物质联合鼻塞持续气道正压呼吸治疗呼吸窘迫综合征新生儿的临床疗效[J].实用临床医学，2018，19（9）：66-67.
[3]	郭杨杨，余加林.肺表面活性物质在重症新生儿呼吸窘迫综合征中的应用[J].医学信息，2018，31（9）：42-45.
[4]	施建莹，周群.肺表面活性物质在预防新生儿呼吸窘迫综合征中的临床应用效果[J].云南医药，2018，39（6）：521-522.
[5]	邵肖梅，叶鸿瑁，丘小汕.实用新生儿学[M].4版.北京：人民卫生出版社，2011：395-398.
[6]	陈国娟.早期应用BNCPAP 预防及治疗新生儿呼吸窘迫综合征的临床研究[D].广州：中山大学，2008：1-36.
[7]	Sweet DG，Carnielli V，Greisen G，et al.欧洲新生儿呼吸窘迫综合征防治共识指南：2016版[J].中华儿科杂志，2017，55（3）：169-176.
[8]	中国医师协会新生儿科医师分会.早产儿呼吸窘迫综合征早期防治专家共识[J].中华实用儿科临床杂志，2018，33（6）：438-440.
[9]	陈蓉蓉.NCPAP治疗新生儿呼吸窘迫综合征（NRDS）的疗效及安全性分析[J].临床医药文献电子杂志，2019，6（A3）：45-46.
[10]	刘琳美.早期应用鼻塞持续正压通气治疗新生儿呼吸窘迫综合征的疗效观察[J].中国药物与临床，2018，18（12）：2219-2221.
[11]	王新杰，关惠娟.NCPAP 联合PS 治疗新生儿呼吸窘迫综合征[J].实用全科医学，2008，6（4）：365-366.
[12]	乔彦霞，韩丽萍，郭秀霞，等.经鼻间歇正压通气辅助呼吸治疗早产儿呼吸窘迫综合征[J].实用儿科临床杂志，2012，27（2）：119-121.
[13]	张俊亮.鼻式间歇正压通气用于早产儿拔管的临床研究[D].广州：南方医科大学，2013：1-68.
[14]	罗可人，唐军.肺表面活性物质的成分和功能研究现状[J].中华妇幼临床医学杂志（电子版），2019，15（2）：137-142.
[15]	赵普，郭忠良.肺泡表面活性物质联合早期NCPAP治疗NRDS的临床疗效观察[J].中国妇幼健康研究，2017，28（3）：279-281.
[16]	李开云.肺表面活性物质在新生儿危急重症的应用[J].转化医学电子杂志，2016，3（1）：68-71.
[17]	孙跃女.不同剂量牛肺泡表面活性物质治疗新生儿呼吸窘迫综合征的疗效观察[J].中国妇幼保健，2018，33（15）：3479-3481.